Efficacy and safety of first-line treatments for metastatic castration-resistant prostate cancer based on phase II and III randomized controlled trials: A PROSTA-MAP systematic review and network meta-analysis.

ABSTRACT:

Background

The landscape of metastatic castration-resistant prostate cancer (mCRPC) treatment has evolved greatly; however, limited data are available regarding its relative efficacy and safety. We conducted a systematic review and network meta-analysis to analyze and compare the effectiveness and safety of first-line therapies for mCRPC, particularly doublet therapy and monotherapy.

Methods

The PubMed, Embase, and Cochrane Library databases were searched from their inception until June 6, 2023. ClinicalTrials.gov and congress abstracts were also searched. We selected randomized controlled trials (RCTs) in English that reported the first-line treatment outcomes of mCRPC. The primary efficacy outcomes included radiographic progression-free survival (rPFS), overall survival (O

SUBMITTER: Guo X 

PROVIDER: S-EPMC12875695 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature